News

Dr. Katey Enfield is an Assistant Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia (UBC), and a Scientist in the Department of Integrative Oncology at the BC Cancer Research Institute (BCCRI). Dr. Enfield received her PhD from UBC under the supervision of Dr. Wan Lam, where she employed a multiomics approach to discover and characterize oncogenes and tumour suppressor genes. 

Five BC Cancer researchers are 2024 recipients of the Michael Smith Health Research BC’s Scholar and Health Professional-Investigator competition, receiving new funding to conduct critical research, develop innovative treatments, and translate their findings into practices that benefit people across BC.

Two BC Cancer research teams are 2024 recipients of the Terry Fox New Frontiers Program Project Grants (PPG), receiving new and renewal funding to advance cancer research and improve treatments. 

Project: Integrated Immunotherapy for Ovarian Cancer

One of this year’s newly funded teams is based in Victoria and led by Dr. Brad Nelson. 

Dr. Ryan Morin (Centre for Lymphoid Cancer) is the co-recipient of the Canadian Cancer Society (CCS) Bernard and Francine Dorval Prize. 

Dr. Morin is a national and international leader in his field of studying how changes to our genes lead to cancer. He has conducted cutting-edge research that has directly helped doctors understand, diagnose and better treat lymphomas. 

Despite decades of advancement in treatment, cancer spreading to multiple parts of the body remains one of the biggest challenges facing patients and their health care teams.

This is particularly true for osteosarcoma, the most common bone cancer in children and teenagers. While survival rates are approximately 70 per cent for people with localized disease, there is a high risk of metastatic spread to the lungs, after which the odds of survival fall dramatically to 20 per cent or less.

In a new study, a team led by Dr. Dean Regier, Senior Scientist in Cancer Control at BC Cancer and co-chair of the MOHCCN Health Technology Assessment Working Group, conducted focus groups with individuals with lived and living experience with cancer to understand their values, expectations, and concerns for enhanced data sharing.